Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity available at the Rutherford Cancer Centre North West in Liverpool from late 2020.
Dr Masinghe graduated in medicine from the University of Dundee in 2003 and completed specialist clinical oncology training at The Edinburgh Cancer Centre.
Following completing specialist clinical oncology training, Dr Masinghe completed a one-year fellowship at The Wellington Blood and Cancer Centre, New Zealand in 2013, where she gained extensive experience in breast radiotherapy. She has been a consultant clinical oncologist at James Cook University Hospital, South Tees NHS Trust since 2016 and also delivers cancer care at the Darlington and Bishop Auckland General Hospitals. Dr Masinghe is also experienced in treating lung, breast, and cancer of unknown primary, and is proficient in delivering both radiotherapy and systemic therapy to these cancer sites.
Proton Beam Therapy
This consultant has received training from the Rutherford Cancer Centres in the delivery of proton beam therapy. The programme, Proton Therapy Clinical Education, in conjunction with The Perelman School of Medicine at the University of Pennsylvania and IBA, the leading proton beam therapy solutions manufacturer, involves oncologists gaining practical experience in Penn’s Roberts Proton Therapy Center – one of the world’s leading centres of proton therapy research and expertise.